Modulation of OPRM1 Alternative Splicing by Morphine and HIV-1 Nef.


Journal

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
ISSN: 1557-1904
Titre abrégé: J Neuroimmune Pharmacol
Pays: United States
ID NLM: 101256586

Informations de publication

Date de publication:
06 2022
Historique:
received: 21 01 2021
accepted: 06 08 2021
pubmed: 23 8 2021
medline: 15 12 2022
entrez: 22 8 2021
Statut: ppublish

Résumé

Clinically used opioids, such as morphine, activate the mu opioid receptor (MOR) encoded by Opioid Receptor Mu 1 (OPRM1) gene. Examination of the opioid receptor genes showed that the human OPRM1 pre-mRNA undergoes extensive alternative splicing events and capable of expressing 21 isoforms. However, characterization of OPRM1 signaling is generalized, and only one isoform (MOR-1) has been extensively studied. Compounding this issue is the increasing significance of intravenous drug abuse in HIV neuropathogenesis. Here, we investigated the molecular impact of morphine and HIV-1 on regulation of OPRM1 pre-mRNA splicing in in vitro and in vivo models. Our results suggested that morphine treatment specifically induces the alternative splicing of MOR-1X isoform among the other isoforms analyzed in neuronal cells. Interestingly, alternative splicing and expression of MOR-1X isoform was also induced in postmortem brain tissues obtained from people with HIV (PWH). Additionally, treatment of control rats with morphine induced alternative splicing of MOR-1X in the brain regions involved in the reward pathways. More interestingly, HIV-1 transgenic (HIV-1Tg) rats, showed an additive induction of MOR-1X isoform with the exposure to morphine. To further assess the possible role of HIV secretory proteins in alternative splicing of OPRM1 gene, we analyzed the impact of HIV-1 Tat, gp120 and Nef proteins on alternative splicing of MOR-1X isoform. While the Tat and gp120 had no visible effects, treatment of neurons with Nef induced MOR-1X alternative splicing that was comparable to treatment with morphine. Altogether, our results suggest that HIV-1 may alter MOR isoform expression with Nef protein by amplifying the rate of MOR-1X alternative splicing induced by morphine.

Identifiants

pubmed: 34420144
doi: 10.1007/s11481-021-10009-4
pii: 10.1007/s11481-021-10009-4
pmc: PMC8859008
mid: NIHMS1751657
doi:

Substances chimiques

Morphine 76I7G6D29C
RNA Precursors 0
Protein Isoforms 0
Receptors, Opioid 0
OPRM1 protein, human 0
Receptors, Opioid, mu 0
nef protein, Human immunodeficiency virus 2 0
nef Gene Products, Human Immunodeficiency Virus 0
nef protein, Human immunodeficiency virus 1 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

277-288

Subventions

Organisme : NIMH NIH HHS
ID : P30 MH092177
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA052284
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA043448
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

J Neuroimmune Pharmacol. 2012 Jun;7(2):332-40
pubmed: 22083500
Nat Rev Neurol. 2016 Apr;12(4):234-48
pubmed: 26965674
Retrovirology. 2011 May 25;8:40
pubmed: 21612582
Neuroscience. 2005;133(1):209-20
pubmed: 15893644
Neuroscience. 2000;100(1):141-53
pubmed: 10996465
J Mol Med (Berl). 2004 Apr;82(4):250-5
pubmed: 14991152
mBio. 2018 Feb 6;9(1):
pubmed: 29437924
Eur J Neurosci. 2002 Sep;16(6):1075-82
pubmed: 12383236
J Cell Physiol. 2016 Jul;231(7):1542-53
pubmed: 26553431
J Biol Chem. 1998 May 29;273(22):13652-7
pubmed: 9593704
J Neurochem. 2004 Nov;91(4):881-90
pubmed: 15525342
Bioessays. 2008 Jan;30(1):38-47
pubmed: 18081010
Int Rev Neurobiol. 2014;118:403-40
pubmed: 25175871
Neuroscience. 2004;127(2):419-30
pubmed: 15262332
Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10811-6
pubmed: 19528663
J Neurochem. 2008 Feb;104(4):937-45
pubmed: 18005002
Int J Clin Exp Med. 2012;5(2):105-23
pubmed: 22567172
AIDS. 2014 Jan 2;28(1):19-30
pubmed: 24413261
Ann Neurol. 1995 Oct;38(4):563-70
pubmed: 7574452
Front Mol Neurosci. 2017 May 29;10:163
pubmed: 28611588
Sci China C Life Sci. 2009 Mar;52(3):253-60
pubmed: 19294350
J Acquir Immune Defic Syndr. 2012 Jul 1;60 Suppl 1:S1-18
pubmed: 22688010
Hum Mol Genet. 2009 Mar 15;18(6):1037-51
pubmed: 19103668
Clin J Pain. 2010 Jan;26 Suppl 10:S3-9
pubmed: 20026962
J Acquir Immune Defic Syndr. 2002 Oct 1;31 Suppl 2:S62-9
pubmed: 12394784
Nat Rev Genet. 2010 May;11(5):345-55
pubmed: 20376054
J Neuroimmune Pharmacol. 2021 Jun;16(2):238-250
pubmed: 33123948
Biochem Biophys Res Commun. 2003 Feb 21;301(4):1057-61
pubmed: 12589820
J Neurovirol. 2016 Apr;22(2):179-90
pubmed: 26407718
Neuroscience. 2001;106(4):833-42
pubmed: 11682168
Regul Pept. 2002 Dec 31;110(1):75-83
pubmed: 12468112
J Biol Chem. 2008 Dec 19;283(51):35614-21
pubmed: 18936093
Brain Res. 2006 Jul 12;1099(1):33-43
pubmed: 16793025
J Neuroimmune Pharmacol. 2018 Jun;13(2):126-142
pubmed: 29159704
Neuroreport. 2001 Oct 8;12(14):3069-72
pubmed: 11568638
J Neurochem. 2003 Sep;86(5):1057-71
pubmed: 12911614
J Neurovirol. 2012 Jun;18(3):181-90
pubmed: 22528479
J Pharmacol Sci. 2003 Dec;93(4):423-9
pubmed: 14737012
Cell Death Dis. 2018 Mar 16;9(4):415
pubmed: 29549313
J Neurovirol. 2006 Jun;12(3):211-8
pubmed: 16877302
Future Virol. 2013 Feb;8(2):121-127
pubmed: 23626655
Front Microbiol. 2015 Sep 08;6:931
pubmed: 26441868
J Cell Physiol. 2018 Dec;233(12):9299-9311
pubmed: 29206302
AIDS Res Treat. 2012;2012:953678
pubmed: 22666564
Cell Death Dis. 2019 Jun 6;10(6):447
pubmed: 31171771
West J Med. 1998 Feb;168(2):93-7
pubmed: 9499742
Brain Behav Immun. 2015 Aug;48:336-49
pubmed: 25733103
J Biol Chem. 2001 Aug 17;276(33):31408-14
pubmed: 11359768
J Neurosci. 2004 Oct 27;24(43):9531-40
pubmed: 15509740
AIDS Res Hum Retroviruses. 2011 Feb;27(2):167-78
pubmed: 20964480
Brain Sci. 2020 Jul 03;10(7):
pubmed: 32635207
Glia. 2010 Oct;58(13):1630-9
pubmed: 20578038
Cell Death Dis. 2017 Jan 12;8(1):e2542
pubmed: 28079886
J Neurovirol. 2016 Apr;22(2):129-39
pubmed: 26631079
FEBS Lett. 1994 Nov 7;354(2):213-6
pubmed: 7957926
AIDS. 1995 Sep;9(9):1001-8
pubmed: 8527071
J Biomed Sci. 2007 Jul;14(4):517-22
pubmed: 17385059

Auteurs

Martina Donadoni (M)

Department of Neuroscience and Center for Neurovirology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA.

Wenfei Huang (W)

Institute of NeuroImmune Pharmacology and Department of Biological Sciences, Seton Hall University, South Orange, NJ, USA.

Shadan S Yarandi (SS)

Department of Neuroscience and Center for Neurovirology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA.

Tricia H Burdo (TH)

Department of Neuroscience and Center for Neurovirology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA.

Sulie L Chang (SL)

Institute of NeuroImmune Pharmacology and Department of Biological Sciences, Seton Hall University, South Orange, NJ, USA. sulie.chang@shu.edu.

Ilker K Sariyer (IK)

Department of Neuroscience and Center for Neurovirology, Temple University Lewis Katz School of Medicine, Philadelphia, PA, 19140, USA. isariyer@temple.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH